AllSight
TNDM · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · 8-K · Item 2.02 · Aug 6, 2026

Revenue missed consensus, but margins and EPS improved meaningfully.

TANDEM DIABETES CARE INC (TNDM) — AllSight decodes this SEC 8-K in plain English, versus what the market expected.

The quarter came in below the revenue bar. Published estimates were roughly $260.1 million of revenue and a $0.32–$0.33 per-share loss; Tandem delivered $254.6 million and a $0.31 loss, meaning a modest revenue miss but a small EPS beat.

$ millions, except per-share dataQ2 2026Q2 2025Published expectation
Sales254.6240.7~260.1
Net loss(21.2)(52.4)
Net loss per share(0.31)(0.78)~(0.32)–(0.33)
Adjusted EBITDA6.4(1.9)
Free cash flow(38.7)(15.7)

The quality of earnings improved, but the top line was not strong enough. Worldwide sales rose 6% year over year, or 5% in constant currency, with U.S. sales up 5%; however, U.S. pump revenue fell 3%, while growth came primarily from supplies and other revenue, up 14% (Sales by Geography). Gross profit increased to $144.8 million from $125.9 million, lifting gross margin to roughly 57% from 52% (Income Statement).

Profitability progress was real, though partly aided by an easier comparison. GAAP operating loss narrowed to $13.8 million from $51.8 million, and adjusted EBITDA turned positive at $6.4 million versus negative $1.9 million (Table D — Reconciliation of GAAP versus Non-GAAP Financial Results). The prior-year quarter included a $20.0 million litigation charge, so the year-over-year improvement overstates the underlying acceleration; even excluding that charge, operating loss improved from $31.9 million to $13.8 million.

Cash generation weakened despite the better income statement. Free cash flow was negative $38.7 million versus negative $15.7 million a year earlier, while cash and short-term investments rose to $456.0 million from $292.7 million largely alongside a sharp increase in convertible senior notes to $602.6 million from $310.0 million (Table D; Table A — Balance Sheets). That leaves the company better funded, but not yet self-funding.

Net read: a mixed quarter leaning slightly negative versus expectations. The EPS beat and operating improvement are constructive, but they do not fully offset the revenue miss, weaker free cash flow, and the fact that pump growth remains soft in the United States. The filing also provides no new numerical 2026 guidance in the furnished release, so the market still needs management’s broader guidance discussion to determine whether the shortfall is timing-related or a more meaningful demand issue.

Read the original 8-K on SEC EDGAR ↗
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.